About Us

Michael H. Tirgan, M.D.

Dr. Michael Tirgan, founder of the company, is a leader in research and treatment of keloid disorder. Since 2008, Dr. Tirgan has treated more than 700 patients with this condition. Currently in his medical practice, Dr. Tirgan provides medical care to 40-50 keloid patients per week.

Dr. Tirgan is a board certified medical oncologist. In 2007, after having treated cancer patients for 15 years on a full time basis, Dr. Tirgan joined the pharmaceutical industry as medical director in oncology drug development. In 2008, Dr. Tirgan focused his medical practice and research on keloid disorder. In November 2011, Dr. Tirgan left Pharma to fully focus his medical practice and his own research on keloid disorder.

Dr. Tirgan has been an attending physician at St. Luke's Roosevelt Hospital in New York since 2003 and an associate attending physician at Rockefeller University Hospital since 2012 with focus on keloid disorder. With over 5 years of full time Pharma experience in clinical development and design and conduct of clinical trials, Dr. Tirgan is now leading Tirgan BioPharmaceuticals to develop innovative products that will help patients with keloid disorder.

Madhav Kamat, Ph.D, R.Ph

Dr. Madhav Kamat, company's Vice President for Formulation and Manufacturing, is an expert in the field of nano/micro suspension technology and sustained release injectable pharmaceuticals. He has been involved in the product/process development (small molecule and biologics), lyophilization, scale-up/technology transfer, and sterile manufacturing of more than 20 injectable commercial products. He is well-recognized expert in the fields of lyophilization, nano-suspension technology, aseptic technology, and other sterile manufacturing processes. He has been active in various initiatives by US-FDA and American Association of Pharmaceutical Scientists (AAPS). His recent interests are formulation and process development of biologics products and IV injectable products of water-insoluble drugs.

Dr. Kamat received his B. Pharm and M. Pharm from Bombay (Mumbai) University and Ph.D. from the College of Pharmacy at the University of Kentucky in Lexington. He worked at Bristol-Myers Squibb Company for the last seventeen years, and most recently as a Director in Manufacturing Technology of Sterile/Biologics products. Prior to BMS, Dr. Kamat worked at Centocor, J&J, and Somatogen. He is also a Registered Pharmacist in the States of Pennsylvania and New Jersey.

With over 25 years of sound industrial experience in large pharmaceutical companies specializing in the area of injectable products and processes, Dr. Kamat is leading development of our innovative injectable products for treatment of keloid disorder.

Nadereh Nouhi

Nadereh Nouhi is the CEO/CFO of the company. She has over two decades of professional experience, providing services in the economics and business strategy areas to various organizations and enterprises in New York City and other national and international localities. In the not-for-profit sector, her clients have included micro-finance institutions and affiliates of the Women's World Banking, mainly in Latin America and Kenya. In the for-profit sector, they include start-up and existing companies in various industries including healthcare and biomedical.

From 1985 to 1992, Ms. Nouhi worked at NYC Economic Development Corporation, current sponsor of Harlem Biospace. She structured and executed corporate and real estate financings for companies in various industries, was on the team developing new financing instruments, including a start-up loan program and a credit-enhanced bond program. She also managed the composite bond program, as well as defining economic development policies in conjunction with special corporate initiatives and specific requirements.

Ms. Nouhi obtained her Bachelors Degree from University of Rochester in 1983 and her MBA in Finance and Accounting from Columbia University in 1985.